Since 2011, the clinic has marketed itself as offering "personalized gene-targeted cancer therapy", which has stirred further controversy, as the treatment bears no relationship to gene-targeted therapy and only superficially incorporates elements of personalized medicine [REF].
Since the mid-1990s, Burzynski registered some sixty clinical trials of antineoplastons and, in December 2010, a Phase III trial which did not open for patient recruitment.